Prostate Cancer Clinical Trial
Official title:
Phase Ib Trial of Encapsulated Rapamycin (eRapa) in Prostate Cancer Patients Under Active Surveillance
Verified date | March 2020 |
Source | Rapamycin Holdings Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is to determine the safety, pharmacokinetics/pharmacodynamics, and immunologic impact of encapsulated rapamycin in patients with low risk prostate cancer under active surveillance. There will be four groups of patients, each receiving a different dose of rapamycin.
Status | Completed |
Enrollment | 15 |
Est. completion date | December 2, 2019 |
Est. primary completion date | December 2, 2019 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - The patient must: - Have pathologically (histologically) proven diagnosis of prostate cancer with a Gleason score =7 (3+4) and already undergoing active surveillance - Be able to give informed consent - Be age 18 or older Exclusion Criteria: - Prostate cancer with a Gleason score >7 - Unable to give informed consent - Age < 18 - Immunosuppressed state (e.g., HIV, use of chronic steroids) - Active, uncontrolled infections - On medications with strong inhibitors or inducers of CYP3A4 and or P-gp. - On agents known to alter rapamycin metabolism significantly (Appendix H) - Have another cancer requiring active treatment (except basal cell carcinoma or squamous cell carcinoma of the skin) - Individuals with a reported history of liver disease (e.g., cirrhosis) - Individuals who are not a good candidate for active surveillance in their treating physician's opinion - Have a medical condition (e.g., anemia, anticoagulated) for which repeated phlebotomy may be problematic. - Uncontrolled hypertension. - Individuals that have abnormal screening vital organ function prior to enrollment - Liver Function Test - Bilirubin >2.0 - Alkaline phosphatase >5x upper limit of normal (ULN) - ALT/AST >2x ULN - Complete Blood Count: - WBC elevated above the normal standard per the testing laboratory - Hgb/Hct below the normal standards of the testing lab - Platelets below the normal standards of the testing lab - Total Cholesterol >240 mg/dL - Triglycerides > 200 mg/dL - Serum creatinine >2 and BUN >30 - Urinary protein: proteinuria >1+ on urinalysis or >1 gm/24hr |
Country | Name | City | State |
---|---|---|---|
United States | UT Health San Antonio | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
Rapamycin Holdings, Inc. dba Emtora Biosciences | Cancer Insight, LLC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary Safety and Tolerability (Incidence of Treatment-Emergent Adverse Events) | To analyze the overall safety of eRapa by evaluating the number, frequency, duration, and relation of toxicity events as defined by the Common Terminology Criteria for Adverse Events (CTCAE) v4.03. | After 4 weeks of treatment in each dosing cohort. | |
Primary | Primary Safety and Tolerability (Incidence of Treatment-Emergent Adverse Events) | To analyze the overall safety of eRapa by evaluating the number, frequency, duration, and relation of toxicity events as defined by the Common Terminology Criteria for Adverse Events (CTCAE) v4.03. | After completion of treatment, approximately 12 weeks, in each dosing cohort. | |
Primary | Primary Safety and Tolerability (Incidence of Treatment-Emergent Adverse Events) | To compare safety between dosing cohorts of eRapa by evaluating the number, frequency, duration, and relation of toxicity events as defined by the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 at the 4 week time point. | This will be completed after all dosing cohorts have been enrolled and treated, anticipated to occur at 1 year. | |
Primary | Primary Safety and Tolerability (Incidence of Treatment-Emergent Adverse Events) | To compare safety between dosing cohorts of eRapa by evaluating the number, frequency, duration, and relation of toxicity events as defined by the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 at the 12 week time point. | This will be completed after all dosing cohorts have been enrolled and treated, anticipated to occur after 1 year. | |
Secondary | Secondary Pharmacokinetics: AUC | Pharmacokinetics of eRapa in blood will be evaluated throughout the trial and compared within and between the dosing cohorts. For cohorts 1 and 2, single dose exposure curves will be generated by assessing the rapamycin levels in whole blood and spot card collection at 0, 0.5, 1, 2, 4, 6, 8, 24, 48, and 72 hrs after the first dose on week 1. Cohorts 3 and 4, exposure curves will be generated during the last week of treatment with blood draws and spot card collection after a dose during the final week at 0, 0.5, 1, 1.5, and 2 hrs. | Cohorts 1 and 2 PK analysis will occur during the first week. Cohorts 3 and 4 PK analysis will occur during week 12 of treatment. | |
Secondary | Secondary Pharmacokinetics: Exposure Trough Levels | Pharmacokinetics of eRapa in blood will be evaluated throughout the trial and compared within and between the dosing cohorts. Cohorts 3 and 4, eRapa troughs will be gathered before the first 5 doses of eRapa during the week 1. | Cohorts 3 and 4 PK analysis will occur during the first week of treatment. | |
Secondary | Secondary Pharmacodynamics: mTOR inhibition in PBMC by assessment of phosphorylation of S6 | Pharmacodynamics of eRapa in blood will be evaluated throughout the trial and compared within and between dosing cohorts. For cohorts 1 and 2, mTOR inhibition in PBMC by assessment of phosphorylation of S6 will also be assessed at 0, 0.5, 1, 2, 4, 6, 8, 24, 48, and 72 hrs after the first dose on week 1. Cohorts 3 and 4, mTor inhibitions will be gathered before the first 5 doses of eRapa during the week 1. In addition, during the last week of treatment after a dose during the final week at 0, 0.5, 1, 1.5, and 2 hrs. | Cohorts 1 and 2 PD analysis will occur during the first week. Cohorts 3 and 4 PD analysis will occur during week 12 of treatment. | |
Secondary | Secondary Pharmacodynamics: mTOR inhibition upon initial dose | Pharmacodynamics of eRapa in blood will be evaluated throughout the trial and compared within and between dosing cohorts. For cohorts 1 and 2, mTOR inhibition in PBMC by assessment of phosphorylation of S6 will also be assessed at 0, 0.5, 1, 2, 4, 6, 8, 24, 48, and 72 hrs after the first dose on week 1. | Cohorts 1 and 2 PD analysis will occur during the first week. | |
Secondary | Secondary Pharmacodynamics: mTOR inhibition first week of daily dosing | Pharmacodynamics of eRapa in blood will be evaluated throughout the trial and compared within and between dosing cohorts. For cohorts 3 and 4, mTOR inhibition in PBMC by assessment of phosphorylation of S6 will also be assessed before the first 5 doses of eRapa during the week 1. | Cohorts 3 and 4 PD analysis will occur during week 12 of treatment. | |
Secondary | Secondary Pharmacodynamics: mTOR inhibition during final week of treatment | Pharmacodynamics of eRapa in blood will be evaluated throughout the trial and compared within and between dosing cohorts. For cohorts 3 and 4, mTOR inhibition in PBMC by assessment of phosphorylation of S6 will also be assessed during the last week of treatment after a dose during the final week at 0, 0.5, 1, 1.5, and 2 hrs. | Cohorts 3 and 4 PD analysis will occur during week 12 of treatment. | |
Secondary | Secondary Immunologic Response: T cell phenotype individually | Immunologic response will be measured and compared from baseline at specified time points throughout the trial. The specific analysis of T cell naïve/memory/effector phenotype. These results will be assessed individually. | Assessments will occur at baseline, during (after 4 weeks), after short-term completion of treatment (after 12 weeks), and long-term completion of treatment (6 months). | |
Secondary | Secondary Immunologic Response: T cell function individually | Immunologic response will be measured and compared from baseline at specified time points throughout the trial. The specific analysis of T cell exhaustion markers (PD-1, LAG3, TIM3), and homing markers (CD62L, CCR7). These results will be assessed individually. | Assessments will occur at baseline, during (after 4 weeks), after short-term completion of treatment (after 12 weeks), and long-term completion of treatment (6 months). | |
Secondary | Secondary Immunologic Response: T cell phenotype within each dosing cohort | Immunologic response will be measured and compared from baseline at specified time points throughout the trial. The specific analysis of T cell naïve/memory/effector phenotype. These results will be assessed within each dosing cohort. | Assessments will occur at baseline, during (after 4 weeks), after short-term completion of treatment (after 12 weeks), and long-term completion of treatment (6 months). | |
Secondary | Secondary Immunologic Response: T cell function within each dosing cohort | Immunologic response will be measured and compared from baseline at specified time points throughout the trial. The specific analysis of T cell exhaustion markers (PD-1, LAG3, TIM3), and homing markers (CD62L, CCR7). These results will be assessed within each dosing cohort. | Assessments will occur at baseline, during (after 4 weeks), after short-term completion of treatment (after 12 weeks), and long-term completion of treatment (6 months). | |
Secondary | Secondary Immunologic Response: T cell phenotype overall study-wide | Immunologic response will be measured and compared from baseline at specified time points throughout the trial. The specific analysis of T cell naïve/memory/effector phenotype. These results will be assessed overall study-wide. | Assessments will occur at baseline, during (after 4 weeks), after short-term completion of treatment (after 12 weeks), and long-term completion of treatment (6 months). | |
Secondary | Secondary Immunologic Response: T cell function overall study-wide | Immunologic response will be measured and compared from baseline at specified time points throughout the trial. The specific analysis of T cell exhaustion markers (PD-1, LAG3, TIM3), and homing markers (CD62L, CCR7). These results will be assessed overall study-wide. | Assessments will occur at baseline, during (after 4 weeks), after short-term completion of treatment (after 12 weeks), and long-term completion of treatment (6 months). | |
Secondary | Secondary Quality of Life Analysis | Quality of life will be assessed and compared to characterize the impact of eRapa before, during, and after treatment by using the National Institute of Health Patient-Reported Outcomes Measurement Information System (PROMIS-29) and Cognition (long form) assessments. | Assessments performed baseline, after completion of therapy (approximately 12 weeks), and after 6 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Active, not recruiting |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |